Severe Respiratory Infections in Rheumatoid Arthritis Patients: An Observational Study of 528 Patients from a Single University Hospital

被引：0

作者：

Dominguez-Casas, Lucia C. ^{[1
]}

Ferraz-Amaro, Ivan ^{[2
]}

Castaneda, Santos ^{[3
]}

Blanco, Ricardo ^{[1
]}

机构：

[1] Hosp Univ Marques Valdecilla, Rheumatol, Immunopathol Grp IDIVAL, Santander 39008, Spain

[2] Hosp Univ Canarias, Rheumatol, Tenerife 38320, Spain

[3] IIS Princesa, Hosp Univ Princesa, Rheumatol, Madrid 28006, Spain

来源：

JOURNAL OF CLINICAL MEDICINE | 2025年 / 14卷 / 04期

关键词：

rheumatoid arthritis; infections; SRI; vaccination; SERIOUS INFECTIONS; RISK-FACTORS; BRITISH SOCIETY; DISEASE; TOCILIZUMAB; MORTALITY; THERAPY; COHORT;

D O I：

10.3390/jcm14041174

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Patients with rheumatoid arthritis (RA) have an increased risk of infections. This may be linked to disease-related factors, immunosuppressive therapy and the presence of comorbidities. Background/Objectives: In an unselected group of RA patients, our aims were to assess the following: (a) the incidence and (b) features of diseases and (c) the predictive factors of severe respiratory infection (SRI). Methods: An observational and retrospective study of all patients with RA included in the vaccination program of our hospital between October 2011 and October 2018 was conducted. The follow-up continued until December 2020. Patients with SRI, defined as those that required hospitalization or at least one dose of intravenous antibiotic treatment in the emergency room, were (a) compared with those not requiring hospital admission and (b) studied for predictive factors of SRI (multivariate analysis adjusted for age and sex). The vaccination program in our hospital includes vaccination against influenza, S. pneumoniae and H. influenzae. Information on the patients, infections and hospitalizations was retrospectively retrieved from the hospital and general physician records. Results: We studied 528 RA patients (409 women/119 men) with a mean age of 58.9 +/- 13.2 years. A total of 55 patients (10.4%) suffered 89 SRIs. The median [IQR] number of hospitalizations per patient was 1.5 [1-2]. Patients with an SRI were older, had had RA for longer and had more comorbidities (hypertension, hypercholesterolemia, diabetes and interstitial lung disease). These patients had more ACPA positivity, more extra-articular manifestations and high disease activity at the time of their vaccination. Treatment with glucocorticoids, methotrexate and leflunomide was seen in a higher number of patients. Predictive factors for SRI were age; time of evolution of RA; associated comorbidities, especially hypertension and diabetes; extra-articular manifestations, especially interstitial lung disease; and treatment with glucocorticoids, methotrexate and leflunomide. Conclusions: Despite being included in a vaccination program, about 10% of our patients required hospitalization due to an SRI. The main predictive factors were certain comorbidities, interstitial lung disease and treatment with glucocorticoids. Predicting SRI in RA patients remains an unmet need.

引用

页数：13

共 40 条

[1]

Turesson C., Comorbidity in rheumatoid arthritis, Swiss Med. Wkly, 146, (2016)

[2]

Castaneda S., Nurmohamed M.T., Gonzalez-Gay M.A., Cardiovascular disease in inflammatory rheumatic diseases, Best Pract. Res. Clin. Rheumatol, 30, pp. 851-869, (2016)

[3]

Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E., Frequency of infection in patients with rheumatoid arthritis compared with controls: A population-based study, Arthritis Rheum, 46, pp. 2287-2293, (2002)

[4]

Atzeni F., Masalab I.F., Di Francoc M., Sarzi-Puttini P., Infections in rheumatoid arthritis, Curr. Opin. Rheumatol, 29, pp. 323-330, (2017)

[5]

Smitten A.L., Choi H.K., Hochberg M.C., Suissa S., Simon T.A., Testa M.A., Chan K.A., The risk of hospitalized infection in patients with rheumatoid arthritis, J. Rheumatol, 35, pp. 387-393, (2008)

[6]

Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Fu B., Ustianowski A.P., Watson K.D., Lunt M., Symmons D.P.M., Et al., Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly, Rheumatology, 50, pp. 124-131, (2011)

[7]

Salliot C., Dougados M., Gossec L., Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses of randomized placebo-controlled trials, Ann. Rheum. Dis, 68, pp. 25-32, (2009)

[8]

Singh J.A., Beg S., Lopez-Olivo M.A., Tocilizumab for rheumatoid arthritis: A Cochrane systematic review, J. Rheumatol, 38, pp. 10-20, (2011)

[9]

Subesinghe S., Rutherford A.I., Ibrahim F., Harris H., Galloway J., A large two-centre study in to rates of influenza and pneumococcal vaccination and infection burden in rheumatoid arthritis in the UK, BMC Musculoskelet. Disord, 17, (2016)

[10]

SujithSubesinghe S., Rutherford A.I., Byng-Maddick R., Hyrich K.L., Galloway J., Recurrent serious infections in patients with rheumatoid arthritis—Results from the British Society for Rheumatology Biologics Register, Rheumatology, 57, pp. 651-655, (2018)

← 1 2 3 4 →